<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03778619</url>
  </required_header>
  <id_info>
    <org_study_id>MG4101-NHL-P1</org_study_id>
    <nct_id>NCT03778619</nct_id>
  </id_info>
  <brief_title>MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin</brief_title>
  <official_title>Multi-center, Open-label, Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy With MG4101 Plus Rituximab in Patient With Relapsed/Refractory Non-Hodgkin's Lymphoma of B-cell Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GC Cell Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GC Cell Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of combined therapy of determined MG4101 dose and&#xD;
      Rituximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will consist of 3 parts; Phase 1 Maximum Tolerated Dose, Phase 1 extended cohort&#xD;
      and Phase 2a.&#xD;
&#xD;
      For Phase 1, those who have a confirmed diagnosis of relapsed/refractory Non-Hodgkin's&#xD;
      Lymphoma (NHL) of B-cell Origin of any subtype will be considered eligible for enrolment.&#xD;
      Each cycle last approximately 28 days.&#xD;
&#xD;
      Once the dose of MG4101 is determined from Phase 1, Phase 2a will commence whereby two&#xD;
      subgroups of patients will be enrolled and will similarly receive up to 6 cycles of treatment&#xD;
      with the recommended Phase 2a dose of MG4101. The 2 subgroups are patients with indolent and&#xD;
      aggressive NHL of B-cell origin respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I - Maximum Tolerated Dose of the dose of MG4101 in combination with Rituximab</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-Limiting Toxicity assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - Objective Response Rate</measure>
    <time_frame>up to 3 years</time_frame>
    <description>central review by Positron Emission Tomograph-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I - Objective Response Rate</measure>
    <time_frame>1 years</time_frame>
    <description>investigator review by Positron Emission Tomograph-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Complete Response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Complete Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II -Partial Response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Partial Response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Overall Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>every 12 weeks after End Of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Time To Progression</measure>
    <time_frame>up to 3 years</time_frame>
    <description>every 12 weeks after End Of Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Time to Response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>every 12 weeks after End Of Treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1&#xD;
MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly&#xD;
Group 1: 1 x 10^7 cells/㎏&#xD;
Group 2: 3 x 10^7 cells/㎏&#xD;
Group 3: 9 x 10^7 cells/㎏&#xD;
Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.&#xD;
Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)&#xD;
Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle&#xD;
Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG4101(allogeneic Natural Killer cell)</intervention_name>
    <description>administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>1 x 10^6 IU/m2, together with MG4101</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>proleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with relapsed or refractory NHL of B-cell origin (mature B cell lymphoma&#xD;
             according to WHO)* who are not considered candidates for intensive anti-lymphoma&#xD;
             therapy.&#xD;
&#xD;
          2. Patients must have received at least 1 prior systemic treatment including anti-CD20&#xD;
             therapy but have received no more than 4 systemic treatments and have:&#xD;
&#xD;
               1. Relapse/Progression and is not considered as a candidate for autologous stem-cell&#xD;
                  transplantation or high-dose immuno-chemotherapy with allogenic antibody&#xD;
                  transplantation.&#xD;
&#xD;
               2. Or Relapsed/progressed after high-dose immuno-chemotherapy with autologous&#xD;
                  stem-cell transplantation.&#xD;
&#xD;
               3. Or Relapsed/progressed after homoplastic stem-cell transplantation performed at&#xD;
                  least 12 weeks ago from C1V1.&#xD;
&#xD;
                    -  For Phase 1 - Any subtype can be enrolled. For Phase 2a - Only below subtype&#xD;
                       can be enrolled in each group. I. Indolent B-cell NHL: Follicular Lymphoma,&#xD;
                       Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma and Marginal Zone Lymphoma&#xD;
                       II. Aggressive B-cell NHL: Diffuse Large B-cell Lymphoma De novo and Diffuse&#xD;
                       Large B-cell Lymphoma transformed&#xD;
&#xD;
          3. According to Positron Emission Tomograph(PET)-CT screening, patients having&#xD;
             lesion/nodules ≥1 with major axis longer than 1.5 cm and the boundaries are clearly&#xD;
             shown.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group score 0 or 1&#xD;
&#xD;
          5. 20 years or older. Age limit for Phase 1 is 65 and for Phase 2a 80.&#xD;
&#xD;
          6. Expected lifespan ≥ 3 month&#xD;
&#xD;
          7. Patients signed Informed consent form&#xD;
&#xD;
          8. Earlier documented result that showed that the patient is positive for CD20 via&#xD;
             immunophenotyping within 6 months of C1V1&#xD;
&#xD;
          9. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for&#xD;
             clinically non-significant toxicities such as alopecia)&#xD;
&#xD;
         10. Those patients who satisfied with following criteria in blood testing, kidney function&#xD;
             test and liver function test:&#xD;
&#xD;
               1. Absolute neutrophil count: Absolute Neutrophil Count ≥ 1,000/ µL (Growth factor&#xD;
                  support at least 2 weeks prior to C1V1)&#xD;
&#xD;
               2. Haemoglobin level ≥ 8g/㎗ (Blood transfusion at least 2 weeks prior to C1V1)&#xD;
&#xD;
               3. Platelet count ≥75,000/µL (Growth factor support/blood transfusion at least 2&#xD;
                  weeks prior to C1V1)&#xD;
&#xD;
               4. Total bilirubin &lt; 3.0㎎/㎗&#xD;
&#xD;
               5. Aspartate aminotransferase(AST) or Alanine Aminotransferase(ALT) ≤ 2.5 x upper&#xD;
                  normal limit (UNL)&#xD;
&#xD;
               6. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients considered appropriate to have stem-cell transplantation after high-dose&#xD;
             chemotherapy as salvage therapy.&#xD;
&#xD;
          2. Patient with Central Nervous System(CNS) lymphoma or any involvement of the CNS.&#xD;
&#xD;
          3. Patients who had a prior history of another malignancy over the last 5 years.&#xD;
&#xD;
          4. Patients with impaired organ functions deemed as significant by investigators.&#xD;
&#xD;
          5. Patients who had prior allogeneic Natural Killer cell treatment.&#xD;
&#xD;
          6. Chronic or active infectious diseases required to be treated at the time of&#xD;
             Investigational Product administration, including Cytomegalovirus(CMV) prophylactic&#xD;
             therapy.&#xD;
&#xD;
          7. Had human immunodeficiency virus (HIV)-positive serology.&#xD;
&#xD;
          8. HBsAg or Hepatitis B virus(HBV) DNA positive or had Hepatitis C virus(HCV) antibodies&#xD;
&#xD;
          9. Patients who received anti-CD20 cancer chemotherapy or immunoglobulin within 4 weeks&#xD;
             of C1V1.&#xD;
&#xD;
         10. Patients who received another investigational drug within 4 weeks of C1V1.&#xD;
&#xD;
         11. Patients with acute graft-versus-host disease(GvHD) ≥Grade 3 or extensive chronic GvHD&#xD;
             within 2 weeks of C1V1.&#xD;
&#xD;
         12. High-dose stem cell support treatment carried out within 6 months of C1V1.&#xD;
&#xD;
         13. Radioimmunotherapy within 4 weeks of C1V1.&#xD;
&#xD;
         14. Patients with major surgery within 4 weeks of C1V1.&#xD;
&#xD;
         15. Patients required to have treatment as having severe diseases such as severe heart&#xD;
             failure or uncontrolled severe heart disease and considered not to be appropriate to&#xD;
             participate in this trial by investigator's decision.&#xD;
&#xD;
         16. Patients on enzyme inducing agents.&#xD;
&#xD;
         17. Patients who have a plan to have vaccination during the trial.&#xD;
&#xD;
         18. Patients with sensitivity to Interleukin-2, cyclophosphamide or fludarabine.&#xD;
&#xD;
         19. Patients with urinary outflow obstruction&#xD;
&#xD;
         20. Patients with history of abnormal cardiac or pulmonary function tests in 6 months&#xD;
             prior to screening visit (Clinically Significant)&#xD;
&#xD;
         21. Patients with history of solid organ allografts&#xD;
&#xD;
         22. Patients with pre-existing or initial presentation of autoimmune disease or&#xD;
             inflammatory disorders, such as Crohn's disease, scleroderma, thyroiditis,&#xD;
             inflammatory arthritis, diabetes mellitus, oculo-bulbar myasthenia gravis, crescentic&#xD;
             Immunoglobulin A(IgA) glomerulonephritis, cholecystitis, cerebral vasculitis,&#xD;
             Stevens-Johnson syndrome and bullous pemphigoid, due to possible exacerbation with&#xD;
             IL-2&#xD;
&#xD;
         23. Concomitant treatment with other cardiotoxic inducing agents&#xD;
&#xD;
         24. Patients who are allergic to Rituximab, Rituximab's excipient (sodium citrate,&#xD;
             polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid) or other&#xD;
             proteins same as Rituximab.&#xD;
&#xD;
         25. From the day of participation of this trial to 12 months from the day of final&#xD;
             administration of Investigational Product, patients who are unable or unwilling to use&#xD;
             appropriate contraceptive methods. (Condom, diaphragm, Intrauterine Device, hormonal&#xD;
             oral contraceptive use, or male partner with vasectomy)&#xD;
&#xD;
         26. Pregnant or lactating women. (Breast-feeding cannot be done within 12 months after&#xD;
             final Investigational Product administration)&#xD;
&#xD;
         27. Patients suspected to have currently known or suspected alcohol abuse or drug abuse&#xD;
             according to investigator's decision.&#xD;
&#xD;
         28. According to investigator's judgement, protocols cannot be followed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National Univ. Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03778619
org study id: MG4101-NHL-P1
nct id: NCT03778619
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
To determine the efficacy and safety of combined therapy of determined MG4101 dose and
      Rituximab.
This trial will consist of 3 parts; Phase 1 Maximum Tolerated Dose, Phase 1 extended cohort
      and Phase 2a.

      For Phase 1, those who have a confirmed diagnosis of relapsed/refractory Non-Hodgkin's
      Lymphoma (NHL) of B-cell Origin of any subtype will be considered eligible for enrolment.
      Each cycle last approximately 28 days.

      Once the dose of MG4101 is determined from Phase 1, Phase 2a will commence whereby two
      subgroups of patients will be enrolled and will similarly receive up to 6 cycles of treatment
      with the recommended Phase 2a dose of MG4101. The 2 subgroups are patients with indolent and
      aggressive NHL of B-cell origin respectively.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Phase I - Maximum Tolerated Dose of the dose of MG4101 in combination with Rituximab
time frame: 28 days
description: Dose-Limiting Toxicity assessment
measure: Phase II - Objective Response Rate
time frame: up to 3 years
description: central review by Positron Emission Tomograph-CT
measure: Phase I - Objective Response Rate
time frame: 1 years
description: investigator review by Positron Emission Tomograph-CT
measure: Phase II - Complete Response
time frame: up to 3 years
description: Complete Response Rate
measure: Phase II -Partial Response
time frame: up to 3 years
description: Partial Response rate
measure: Phase II - Overall Survival
time frame: up to 3 years
description: every 12 weeks after End Of Treatment
measure: Phase II - Time To Progression
time frame: up to 3 years
description: every 12 weeks after End Of Treatment
measure: Phase II - Time to Response
time frame: up to 3 years
description: every 12 weeks after End Of Treatment
arm group label: single arm
arm group type: Experimental
description: Phase 1
MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly
Group 1: 1 x 10^7 cells/㎏
Group 2: 3 x 10^7 cells/㎏
Group 3: 9 x 10^7 cells/㎏
Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.
Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)
Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle
Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1.
intervention type: Drug
intervention name: Rituximab
description: weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
arm group label: single arm
other name: Mabthera
intervention type: Drug
intervention name: Fludarabine
description: administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
arm group label: single arm
other name: Fludara
intervention type: Drug
intervention name: Cyclophosphamide
description: administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
arm group label: single arm
other name: Endoxan
intervention type: Biological
intervention name: MG4101(allogeneic Natural Killer cell)
description: administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
arm group label: single arm
intervention type: Drug
intervention name: Interleukin-2
description: 1 x 10^6 IU/m2, together with MG4101
arm group label: single arm
other name: proleukin
criteria: 
gender: All
minimum age: 20 Years
maximum age: 80 Years
healthy volunteers: No
last name: Won Seog Kim, Dr.
role: Principal Investigator
affiliation: Samsung Medical Center
facility: 
facility: 
facility: 
country: Korea, Republic of
responsible party type: Sponsor
mesh term: Lymphoma
mesh term: Lymphoma, Non-Hodgkin
mesh term: Cyclophosphamide
mesh term: Rituximab
mesh term: Fludarabine
mesh term: Interleukin-2
sharing ipd: No